Clinical Efficacy of Bisphosphonates and Monoclonal Antibodies on Bone Mineral Density Following Skeletal Fractures

Overview

Journal J Clin Orthop Trauma

Specialty Orthopedics

Date 2022 Sep 26

PMID 36161063

Authors

Priya Sharma

Oday Al-Dadah

Affiliations

Soon will be listed here.

Abstract

Background: Bisphosphonates and monoclonal antibodies are drugs primarily developed to inhibit osteoclast-mediated bone resorption and are used to treat an array of skeletal pathologies. Their use is aimed at increasing bone health and therefore reducing fracture risks. The aim of this study was to evaluate the effectiveness of bone protection therapy on improving bone mineral density (BMD) in patients following a fracture.

Methods: Inclusion criteria consisted of patients who sustained a skeletal fracture and were subsequently commenced on bone protection therapy. Dual-energy X-ray Absorptiometry (DEXA) scans were performed at baseline and following a consented period of drug therapy. Bone health data included T-Scores, Z-Scores, FRAX Major, FRAX Hip and BMD. The clinical effectiveness of four bisphosphonates (alendronate, risedronate, pamidronate and zoledronate) and one monoclonal antibody (denosumab) were evaluated.

Results: A total of 100 patients were included in the study. Overall, bone protection therapy significantly improved Z-score Hip, Z-score Spine, T-score Spine and BMD Spine (p < 0.05). There was a marked difference between drug therapies. Denosumab and zoledronate were associated with the greatest treatment effect size. Alendronate only improved Z-score Spine and Z-score Hip (p < 0.05). Pamidronate and risedronate did not demonstrate any statistically significant improvement across any DEXA parameter.

Conclusion: Overall, bisphosphonates/monoclonal antibodies confer beneficial effects on bone health as measured by DEXA scans in patients following skeletal fractures. However, the magnitude of improvement varies among the commonly used drugs. Alendronate, zoledronate and denosumab were associated with greatest therapeutic benefit. Bone protection therapy did not improve fracture risk of patients (FRAX scores).

References

Drake M, Clarke B, Khosla S . Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83(9):1032-45. PMC: 2667901. DOI: 10.4065/83.9.1032. View

Anastasilakis A, Polyzos S, Makras P . THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol. 2018; 179(1):R31-R45. DOI: 10.1530/EJE-18-0056. View

Recker R, Delmas P, Halse J, Reid I, Boonen S, Garcia-Hernandez P . Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. 2007; 23(1):6-16. DOI: 10.1359/jbmr.070906. View

Nancollas G, Tang R, Phipps R, Henneman Z, Gulde S, Wu W . Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2005; 38(5):617-27. DOI: 10.1016/j.bone.2005.05.003. View

Sanderson J, Martyn-St James M, Stevens J, Goka E, Wong R, Campbell F . Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis. Bone. 2016; 89:52-58. DOI: 10.1016/j.bone.2016.05.013. View

Watts N, Geusens P, Barton I, Felsenberg D . Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005; 20(12):2097-104. DOI: 10.1359/JBMR.050814. View

Jansen J, Bergman G, Huels J, Olson M . The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum. 2010; 40(4):275-84.e1-2. DOI: 10.1016/j.semarthrit.2010.06.001. View

Rodan G, Fleisch H . Bisphosphonates: mechanisms of action. J Clin Invest. 1996; 97(12):2692-6. PMC: 507360. DOI: 10.1172/JCI118722. View

Eekman D, Vis M, Bultink I, Derikx H, Dijkmans B, Lems W . Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates. BMC Musculoskelet Disord. 2009; 10:86. PMC: 2714827. DOI: 10.1186/1471-2474-10-86. View

10.

Miller R, Chretien K, Meoni L, Liu Y, Klag M, Levine M . Comparison of intravenous pamidronate to standard therapy for osteoporosis: use in patients unable to take oral bisphosphonates. J Clin Rheumatol. 2005; 11(1):2-7. DOI: 10.1097/01.rhu.0000152141.47663.e4. View

11.

Silverman S, Calderon A . The utility and limitations of FRAX: A US perspective. Curr Osteoporos Rep. 2010; 8(4):192-7. PMC: 2947011. DOI: 10.1007/s11914-010-0032-1. View

12.

Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A . A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess. 2016; 20(78):1-406. PMC: 5107884. DOI: 10.3310/hta20780. View

13.

Lewiecki E . Denosumab: an investigational drug for the management of postmenopausal osteoporosis. Biologics. 2009; 2(4):645-53. PMC: 2727882. DOI: 10.2147/btt.s2082. View

14.

Beaudoin C, Jean S, Bessette L, Ste-Marie L, Moore L, Brown J . Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int. 2016; 27(9):2835-2844. DOI: 10.1007/s00198-016-3607-6. View

15.

Rashki Kemmak A, Rezapour A, Jahangiri R, Nikjoo S, Farabi H, Soleimanpour S . Economic burden of osteoporosis in the world: A systematic review. Med J Islam Repub Iran. 2021; 34:154. PMC: 7787041. DOI: 10.34171/mjiri.34.154. View

16.

Crandall C, Newberry S, Diamant A, Lim Y, Gellad W, Booth M . Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med. 2014; 161(10):711-23. DOI: 10.7326/M14-0317. View

17.

Lin T, Wang C, Cai X, Zhao X, Shi M, Ying Z . Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract. 2012; 66(4):399-408. DOI: 10.1111/j.1742-1241.2011.02806.x. View

18.

Sinigaglia L, Varenna M, Casari S . Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders. Clin Cases Miner Bone Metab. 2012; 4(1):30-6. PMC: 2781185. View

19.

Morgan S, Prater G . Quality in dual-energy X-ray absorptiometry scans. Bone. 2017; 104:13-28. DOI: 10.1016/j.bone.2017.01.033. View

20.

Hanley D, Adachi J, Bell A, Brown V . Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012; 66(12):1139-46. PMC: 3549483. DOI: 10.1111/ijcp.12022. View